European Companies Search Engine
UK funding (£1,247,099): Rapid Metabolite Analyser for Medicines Manufacture Ukri1 Feb 2018 UK Research and Innovation, United Kingdom
Overview
Text
Rapid Metabolite Analyser for Medicines Manufacture
| Abstract | "Many modern medicines are no longer produced in chemistry labs, but instead in big bio-reactors where cells produce the medicines (aka biotherapeutics). This is similar to what happens when beer is brewed or yoghurt is made. Like any living organism, different strains of cells vary subtly with some much more effective at making high quality medicines than others. Thus it is important to select the best cell line for the medicine you are trying to produce. In addition, when growing cells it is important to regularly check that they are healthy and have the right levels of nutrients to ensure that a high quality medicine is produced at highest possible yield. An excellent parameter to monitor the health of these cell cultures is a diverse group of chemicals known as metabolites. These include nutrients (vitamins, sugars, amino acids, fats), but also metabolic by-products (like lactate) or toxins. Currently, whilst they are promising treatments, biotherapeutics are expensive to manufacture, thus are a big drain on a country's medicines budget. The close and repeated monitoring of multiple metabolites in cell culture processes could significantly improve the efficiency and cost of manufacturing biotherapeutics and avoid costly culture failures, enabling better medicines to be produced more cheaply, ultimately benefitting patients. Despite the noted advantages of metabolite monitoring, only a few are measured at present and at infrequent points in the process. This is because current measurement instruments are very expensive to purchase, each test is expensive, the machines are difficult to operate and slow in giving results. Our solution is to develop a breakthrough metabolite analyser that overcomes the above drawbacks. Our analyser will be able to quickly measure many different metabolites in one sample. Importantly it will be easy to use and much cheaper to purchase and run. This will make it usable at many stages of medicines manufacture, ultimately leading to new medicines reaching more patients." |
| Category | Collaborative R&D |
| Reference | 104200 |
| Status | Closed |
| Funded period start | 01/02/2018 |
| Funded period end | 31/12/2021 |
| Funded value | £1,247,099.00 |
| Source | https://gtr.ukri.org/projects?ref=104200 |
Participating Organisations
| CAMENA BIOSCIENCE LIMITED |
£893,568.00 |
| CENTRE FOR PROCESS INNOVATION LIMITED |
£353,531.00 |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Camena Bioscience Ltd., Saffron Walden.
The visualizations for "Camena Bioscience Ltd. - UK funding (£1,247,099): Rapid Metabolite Analyser for Medicines Manufacture"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
